Results of studies using lamivudine and interferon combination in the treatment of chronic hepatitis B are not consistent or conclusive. This study aimed to evaluate the efficacy of interferon plus lamivudine use versus single lamivudine in anti-HBe-positive chronic hepatitis B.
Methods
Eighty patients were treated with either lamivudine or lamivudine plus simultaneously started interferon. Patients were assigned in groups according to random allocation rule. Lamivudine was given 150 mg/day for 96 weeks in each group; interferon was administered 10 MU three times a week for 24 weeks in the combination therapy group.
Results
Alanine aminotransferase (ALT) normalization was achieved earlier in patients treated with lamivudine alone. At the end of treatment, there was no difference between the groups with respect to HBV DNA negativity, ALT normalization and breakthrough rate. Histological improvement was remarkable in each group, but fibrosis score and necro-inflammatory activity were much lower in lamivudine-treated patients.
Conclusions
Addition of interferon to the lamivudine regimen does not increase the effectiveness of the treatment. Considering the side effects of interferon treatment, this combination seems not to be convenient for anti-HBe-positive chronic hepatitis B.
EstebanR.Management of chronic hepatitis B: an overview.Seminars in Liver Disease2002; 22(Suppl. 1): 1–6.
3.
WongD.K., CheungA.M., O'RourkeK., NaylorC.D., DetskyA.S., & HeathcoteJ.Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B; A meta-analysis.Annals of Internal Medicine1993; 119: 312–323.
4.
OliveriF., SantantonioT., BellatiG., ColombattoP., MelsG.C., CarrieroL., DastoliG., PastoreG., IdeoG., BoninoF., & BrunettoM.R.Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon.American Journal of Gastroenterology1999; 94: 1366–1372.
5.
ManesisE.K., & HadziyannisS.J.Interferon-α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.Gastroenterology2001; 121: 101–109.
6.
LokA.S., HeathcoteE.J., & HoofnagleJ.H.Management of hepatitis B: 2000–summary of a workshop.Gastroenterology2001; 120: 1828–1853.
7.
LeungN.W., LaiC.L., ChangT.T., GuanR., LeeC.M., NgK.Y., LimS.G., WuP.C., DentJ.C., EdmundsonS., CondreayL.D., & ChienR.N.Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.Hepatology2001; 33: 1527–1532.
8.
LeungN.Treatment of chronic hepatitis B: case selection and duration of therapy.Journal of Gastroenterology & Hepatology2002; 17: 409–414.
9.
SuzukiF., SuzukiY., TsubotaA., AkutaN., SomeyaT., KobayashiM., SaitohS., AraseY., IkedaK., & KumadaH.Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy.Journal of Hepatology2002; 37: 824–830.
10.
XiongX., FloresC., YangH., TooleJ.J., & GibbsC.S.Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.Hepatology1998; 28: 1669–1673.
11.
PerrilloR., SchiffE., YoshidaE., StatlerA., HirschK., WrightT., GutfreundK., Lamy, & MurrayA.Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.Hepatology2000; 32: 129–134.
12.
MarcellinP.Advances in therapy for chronic hepatitis B.Seminars in Liver Disease2002; 22(Suppl. 1): 33–36.
13.
CherringtonJ.M., MulatoA.S., FullerM.D., & ChenM.S.Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxyethyl]adenine in vitro.Antimicrobial Agents & Chemotherapy1996; 40: 2212–2216.
14.
DelaneyW.E., LocarniniS., & ShawT.Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.Antiviral Chemistry & Chemotherapy2001; 12: 1–35.
15.
MutimerD., NaoumovN., HonkoopP., MarinosG., AhmedM., deManR., McPhilipsP., JohnsonM., WilliamsR., EliasE., & SchalmS.Combination alpha-interferon and lamivudine therapy for alpha-interferon–resistant chronic hepatitis B infection: results of a pilot study.Journal of Hepatology1998; 28: 923–929.
16.
SchalmS.W., HeathcoteJ., CianciaraJ., FarrellG., ShermanM., WillemsB., DhillonA., MooratA., BarberJ., & GrayD. F.International Lamivudine Study Group. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.Gut2000; 46: 562–568.
17.
SchiffE.R., KarayalcinS., GrimmI., PerilloR., DienstagJ., HusaP., SchalmS., CrowtherL., SullivanM., WoessnerM., McPhilipsP., BrownN., & the International Lamivudine Investigator Group. A placebo controlled study of lamivudine and interferon α-2β in patients with chronic hepatitis B who previously failed interferon therapy.Hepatology1998; 28: 388A.
18.
TatulliI., FrancavillaR., RizzoG.L., VinciguerraV., IerardiE., AmorusoA., PanellaC., & FrancavillaA.Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.Journal of Hepatology2001; 35: 805–810.
19.
SantantonioT., NiroA. G., SinisiE., GioacchinoL., InsalataM., GuastadisegniA., FacciorussoD., GravineseE., AndriulliA., & PatoreG.Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study.Journal of Hepatology2002; 36: 799–804.
20.
BarbaroG., ZechiniF., PellicelliA.M., FrancavillaR., ScottoG., BaccaD., BrunoM., BabudieriM., AnneseM., MatarazzoF., Di StefanoG., & BarbariniG.Long-term efficacy of interferon α-2β and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B.Journal of Hepatology2001; 35: 406–411.
21.
HadziyannisS.J., PapatheodoridisG.V., DimouE., LarasA., & PapaioannouC.Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Hepatology2000; 32: 847–851.
22.
KnodellR.G., IshakK.G., BlackW.C., ChenT.S., CraigR., KaplowitzN., KiernanT.W., & WollmanJ.Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.Hepatology1981; 1: 431–435.
23.
TassopoulosN.C., VolpesR., PastoreG., HeathcoteJ., ButiM., GoldinR.D., HawleyS., BarberJ., CondreayL., & GrayD. F.Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.Hepatology1999; 29: 889–896.
24.
ButiM., CotrinaM., JardiR., de CastroE.C., Rodriguez-FriasF., Sanchez-AvilaF., EstebanR., & GuardiaJ.Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.Journal of Viral Hepatology2001; 8: 270–275.
25.
SangfeltP., UhnooI., HollanderA., LindhG., & WeilandO.Lamivudine and famciclovir combination therapy with or without addition of interferon-α-2β for HBeAg-positive chronic hepatitis B: a pilot study.Scandinavian Journal of Infectious Diseases2002; 34: 505–511.
26.
DikiciB., BosnakM., BosnakV., DagliA., DavutogluM., YagciR.V., & HaspolatK.Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone.Pediatrics International2002; 44: 517–521.
27.
SelimogluM.A., AydogduS., UnalF., ZeytinogluA., YuceG., & YagciR.V.Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children.Pediatrics International2002; 44: 404–408.
28.
PerrilloR.P., LaiC.L., LiawY.F., DienstagJ.L., SchiffE.R., SchalmS.W., HeathcoteE.J., BrownN.A., AtkinsM., WoessnerM., & GardnerS.D.Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.Hepatology2002; 36: 186–194.
29.
LauD.T., KhokharM.F., DooE., GhanyM.G., HerionD., ParkY., KleinerD.E., SchmidP., CondreayL.D., GauthierJ., KuhnsM.C., LiangT.J., & HoofnagleJ.H.Long-term therapy of chronic hepatitis B with lamivudine.Hepatology2000; 32(4 Pt 1): 828–834.
30.
ZoulimF.Evaluation of novel strategies to combat hepatitis B virus targeting wild-type and drug-resistant mutants in experimental models.Antiviral Chemistry & Chemotherapy2001; 12(Suppl. 1): 131–142.
31.
MutimerD.Hepatitis B virus antiviral drug resistance: from the laboratory to the patient.Antiviral Therapy1998; 3: 243–246.
32.
LiawY.F., ChienR.N., YehC.T., TsaiS.L., & ChuC.M.Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.Hepatology1999; 30: 567–572.
33.
JanssenH.L., GerkenG., CarrenoV., MarcellinP., NaoumovN. V., CraxiA., Ring-LarsenH., KitisG., van HattumJ., de VriesR.A., MichielsenP.P., ten KateF.J., HopW.C., HeijtinkR.A., HonkoopP., & SchalmS.W.Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment.The European Concerted Action on Viral Hepatitis (EUROHEP) Hepatology1999; 30: 238–243.
